Fusion Pharmaceuticals to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) will participate in a fireside chat at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 17, 2020, at 11:00am EDT.

Rhea-AI Summary

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) will participate in a fireside chat at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 17, 2020, at 11:00am EDT. The presentation will feature CEO John Valliant, CFO John Crowley, and CMO James O'Leary. Investors can access the live webcast on the company's website, with a replay available for 90 days. Fusion specializes in developing next-generation radiopharmaceuticals using Fast-Clear linker technology, with its lead program FPI-1434 in Phase 1 clinical trials.

Argus Session date unavailable

-0.24% session move Open Argus

Details

News Market Reaction – FUSN

The recorded move for FUSN in the trading session of this news was -0.24%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAMILTON, ON and BOSTON, Sept. 10, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a "fireside chat" presentation at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Thursday, September 17, 2020 at 11:00am EDT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D., Chief Financial Officer John Crowley, and Chief Medical Officer James O'Leary, M.D.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.  

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-morgan-stanley-virtual-18th-annual-global-healthcare-conference-301127433.html

SOURCE Fusion Pharmaceuticals Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What event will Fusion Pharmaceuticals attend on September 17, 2020?

Fusion Pharmaceuticals will participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference.

Who will represent Fusion Pharmaceuticals at the Morgan Stanley conference?

CEO John Valliant, CFO John Crowley, and CMO James O'Leary will represent Fusion Pharmaceuticals.

How can I access the presentation by Fusion Pharmaceuticals at the conference?

The presentation can be accessed via a live webcast on the company's website.

What is the focus of Fusion Pharmaceuticals?

Fusion Pharmaceuticals focuses on developing next-generation radiopharmaceuticals as precision medicines.

What is Fusion Pharmaceuticals' lead clinical program?

Fusion's lead program is FPI-1434, which is currently in a Phase 1 clinical trial.